New research suggests that GLP-1 weight loss drugs could significantly reduce mortality rates in the U.S. by 2045, addressing obesity’s role in leading causes of death.
A recent study indicates that GLP-1 drugs, commonly used for diabetes and weight loss, could lead to a notable decrease in mortality rates among Americans. Researchers from Swiss Re, a reinsurance company based in Zurich, Switzerland, project that these medications could result in a 6.4% reduction in all-cause mortality in the United States by the year 2045. In comparison, the United Kingdom is expected to see a reduction of over 5% in mortality rates over the same period.
Both the U.S. and the U.K. are grappling with high obesity rates and have seen a “strong uptake” of GLP-1 drugs, according to the researchers’ findings. The United States has the highest obesity rate in the world, with more than 40% of adults classified as obese. In the U.K., approximately 30% of adults fall into the same category.
Obesity is a significant factor contributing to the stagnation of life expectancy, as it is linked to 70% of the leading causes of death in high-income countries. These causes include heart disease, stroke, Alzheimer’s disease, and various forms of cancer. The researchers noted that by improving baseline risk factors, GLP-1 drugs could lead to long-term reductions in mortality, potentially saving millions from premature death.
To maximize the benefits of GLP-1 medications, experts emphasize the importance of implementing lifestyle changes that promote long-term health improvements. Without sustainable changes such as diet and exercise, individuals may experience weight regain and rebound effects, as supported by various studies.
Paul Murray, the CEO of Life & Health Reinsurance at Swiss Re, highlighted the potential of GLP-1 drugs to combat the obesity epidemic. In a press release, he stated, “Our research underscores that the full benefit will come from going beyond medication.” He added that insurers have a unique opportunity to foster partnerships, support policy initiatives, and encourage individuals to make meaningful lifestyle changes focused on prevention.
Murray further noted, “If we get this right, we can strengthen the insurance safety net and contribute to people living longer, healthier lives.”
Recent findings also indicate that GLP-1 medications can improve a range of health conditions beyond weight loss and diabetes. These include issues related to heart health, kidney function, liver conditions, skin disorders, arthritis, cognitive decline, addiction, and even certain cancers.
Dr. Sue Decotiis, a triple board-certified weight loss physician based in New York, confirmed in an interview that patients have reported improvements in various health conditions while using these medications. She explained that fat cells, which are reduced through the action of GLP-1 drugs, produce cytokines that can lead to inflammation in the body. This inflammation is associated with autoimmune diseases, cancer, and other health issues.
“By reducing the volume of fat cells in the body, we reduce all these inflammatory cytokines,” Dr. Decotiis stated. “And that’s why we see a lot of the effects that we see.” She emphasized the importance of using these medications responsibly, treating both the drugs and the body with respect. “This is a wonderful tool if it’s used the right way,” she added.
As the research unfolds, the potential of GLP-1 drugs to enhance public health and extend life expectancy appears promising, provided that individuals also commit to healthier lifestyles.
Source: Original article